BioMarin's Expanding Product Portfolio Will Lead To Gains In 2013 Seeking Alpha Shares of BioMarin Pharmaceuticals (BMRN) have risen roughly 40% in 2012, driven by solid Phase III data for BMRN's lead investigational product GALNS, a treatment for Morquio A Syndrome (MPS) IVA. But with BMRN supported by a market capitalization of ...
No comments:
Post a Comment